This division is dying. Nothing innovative in the past 10 years. They own the ENT OR space because of three products: Navigation, Sinus power and Nerve monitoring. Everything else is non-technology driven (aka non Core) and the company thinks it doesn't matter (so they don't market it or pay reps for selling it) even though it represents substantial volume. So it erodes every year as they try to motivate reps to focus on the big 3, which are all now in their 2nd or 3rd generation of retread-relaunch with no real innovation. High tenure reps have 90%+ market share and cannot grow enough by farming, and have little opportunity to hunt, so they are beginning to leave. They all hope for a new capital platform with a disposable stream (or a new innovative upgrade) which has so far been unobtainable through invention or acquisition. They can't even launch a sinus pack or a suction. Mother Medtronic won't put any money into ENT because the Sx reimbursement and ROI is just not as attractive as other business sectors. It's a shame. ENT has robotics, implantable devices and other innovation, but not from Medtronic. ENT will continue to shrink in significance until the cash cow runs out of milk, then MN will gaze on a sick starved cow and try to see if they can consume or sell the beef before it dies completely. Then they will say new competition and reimbursement changed our positive. The truth is, division mergers with sexy-er platforms stole ENTs seat at the table.